NDA 022287 · Takeda Pharms USA
Dexilant
Dexlansoprazole · Oral · Proton Pump Inhibitor
Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jan 30, 2009
Approved uses
5
Original approval plus efficacy supplements
Registered trials
288
83 Phase 3, 12 recruiting
FAERS reports
41,708
33,723 serious, 3,737 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 17, 2025.
DEXILANT is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn. ( 1.2 ) Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) 1.1 Healing of Erosive Esophagitis DEXILANT ® is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis and Relief of Heartburn DEXILANT is indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. 1.3 Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.
Mechanism: Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 8, 2016 Supplement 22 · Efficacy LabelLetter
- Jul 8, 2016 Supplement 23 · Efficacy LabelLetter
- Jul 8, 2016 Supplement 21 · Efficacy LabelLetter
- Jun 17, 2011 Supplement 8 · Efficacy LabelLetter
- Jan 30, 2009 Original approval · Type 2 - New Active Ingredient ReviewLetterOther Important Information from FDA
2 products under this application
- DEXILANT · DEXLANSOPRAZOLE 30MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
- DEXILANT · DEXLANSOPRAZOLE 60MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexlansoprazole" as an intervention, any sponsor and status, largest first.
- Helicobacter Eradication Aspirin TrialPivotal-lookingCompleted
University of NottinghamAcademic, hospital or other
NCT01506986 · 30,024 participants · Start Mar 2012 · Primary completion Oct 31, 2017
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg; Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg · For: Gastrointestinal Ulcer Haemorrhage; Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Durham, United Kingdom · 6 sites in all
- Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General PopulationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT02112214 · 5,224 participants (planned) · Start Jun 2014 · Primary completion Dec 2029
Drug: 10-day bismuth-based quadruple therapy · For: Gastric Cancer; Helicobacter Pylori Infection
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 11 sites in all
- Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00251719 · 2,054 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Dexlansoprazole MR; Dexlansoprazole MR and 1 more · For: Esophagitis, Reflux; Esophagitis, Peptic
Sites: Anniston, Alabama; Hueytown, Alabama; Huntsville, Alabama · 144 sites in all
- Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00251693 · 2,038 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Dexlansoprazole MR; Dexlansoprazole MR and 1 more · For: Esophagitis, Reflux; Esophagitis, Peptic
Sites: Alabaster, Alabama; Birmingham, Alabama; Huntsville, Alabama · 140 sites in all
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT01061437 · 1,859 participants · Start Jun 2009 · Primary completion Jul 2011
Drug: PACx14; PACMx5 and 1 more · For: Helicobacter Pylori Infection
Sites: Santiago, Chile; Cali, Colombia; San José, Costa Rica · 7 sites in all
- Gastric Cancer Prevention in the Family Members by Helicobacter Pylori EradicationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT01678027 · 1,838 participants · Start Nov 2004 · Primary completion Dec 2018
Drug: Placebo; LAC triple therapy · For: Gastric Cancer; Helicobacter Pylori Infection; Family Members
Sites: Goyang-si, South Korea
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02139046 · 1,790 participants · Start Apr 2014 · Primary completion Nov 2015
Drug: Febuxostat IR; Febuxostat XR and 4 more · For: Gout
Sites: Binghamton, Alabama; Birmingham, Alabama; Huntsville, Alabama · 192 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease16,102
- acute kidney injury7,811
- renal failure6,722
- end stage renal disease4,888
- renal injury4,339
- drug ineffective2,627
- fatigue2,442
- off label use2,345
- nausea2,244
- tubulointerstitial nephritis2,191
- diarrhoea2,006
- headache1,972
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 114 |
| 2011 | 375 |
| 2012 | 710 |
| 2013 | 707 |
| 2014 | 989 |
| 2015 | 1,641 |
| 2016 | 2,105 |
| 2017 | 1,672 |
| 2018 | 13,439 |
| 2019 | 7,819 |
| 2020 | 2,724 |
| 2021 | 2,416 |
| 2022 | 1,915 |
| 2023 | 1,556 |
| 2024 | 1,362 |
| 2025 | 1,292 |
| 2026 | 869 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dexilant (Dexlansoprazole)
2024 spending
$41.0M
Beneficiaries
20,798
86,176 claims
Per beneficiary
$1,972
$9.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $651,674,922 |
| 2021 | $675,684,020 |
| 2022 | $407,784,107 |
| 2023 | $87,349,224 |
| 2024 | $41,017,762 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
Zhuang Q, Chen S, Zhou X, et al. · Am J Gastroenterol 2024 · Systematic Review, Comparative Study
- Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.
Zou S, Ouyang M, Cheng Q, et al. · Pharmacotherapy 2024 · Systematic Review, Network Meta-Analysis
- The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Nunes GP, Silveira TC, Marciano JVS, et al. · Int J Mol Sci 2024 · Meta-Analysis, Systematic Review
- Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan.
Rimmani HH, Rustom LBO, Rahal MA, et al. · Dig Dis 2019 · Clinical Trial
- Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L, Liu J, Zheng Y, et al. · Clin Drug Investig 2019 · Clinical Trial, Comparative Study
- Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA, Pilmer B, Hunt B, et al. · Aliment Pharmacol Ther 2013 · Clinical Trial, Phase III, Comparative Study
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.